Optimized drug‐coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: Tack Optimized Balloon Angioplasty (TOBA) III 24‐month results in standard and long lesions

Abstract

AbstractObjectiveThe Tack Endovascular System is a minimal‐metal dissection repair device that is purpose‐built to treat post‐percutaneous angioplasty (PTA) arterial dissections in patients with peripheral arterial disease (PAD). The Tack Optimized Balloon Angioplasty (TOBA) III trial evaluated the safety and effectiveness of the Tack Endovascular System in patients with superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) dissection after PTA with a drug‐coated balloon (DCB). The objective of this study is to report the results in the standard‐ (SL) and long‐lesion (LL) cohorts through 24 months.DesignThe TOBA III study was a prospective, multicenter, single‐arm study including patients suffering from Rutherford category 2–4 PAD. Outcomes were assessed according to pre‐specified lesion length in SL ( ≥ 20 mm and ≤150 mm) and LL ( > 150 mm and ≤250 mm) cohorts. Follow‐up was through 24 months.ResultsTOBA III enrolled 201 patients, 169 patients in the SL cohort and 32 in the LL cohort. At 24 months, the Kaplan–Meier estimates of freedom from major adverse events were 91.7% and 82.6% for the SL cohort and LL cohort, respectively. Kaplan–Meier estimates of freedom from clinically driven‐target lesion revascularization (CD‐TLR) were 92.3% in the SL cohort and 82.6% in the LL cohort. At 24 months, 78.8% of SL patients and 69.2% of LL patients experienced an improvement of >2 Rutherford categories (both cohorts p < 0.001). The baseline ankle‐brachial index improved from 0.68 ± 0.18 to 0.93 ± 0.16 in the SL (p < 0.001) and from 0.62 ± 0.23 to 0.87 ± 0.15 in the LL cohort (p < 0.001) at 24 months.ConclusionThe 24‐month results of the TOBA III trial support the safety and effectiveness of the Tack Endovascular System in patients who required post‐PTA dissection repair in the SFA and PPA following DCB angioplasty for claudication and rest pain. In both the SL and LL cohorts, Tack placement was associated with sustained freedom from CD‐TLR through 24 months as well as sustained improvements in Rutherford categories, ankle‐brachial index, and quality of life.